Spasticity Related to Any Cause Except Cerebral Palsy
Conditions
Brief summary
The aim of the study is to describe treatment outcomes of abobotulinumtoxinA (aboBoNT-A) and onabotulinumtoxinA (onaBoNT-A) treatments, after one injection of either treatment, in toxin-naïve adult patients with upper and/or lower limb spasticity at a single National Health Service (NHS) centre in the United Kingdom (UK).
Interventions
None listed
Sponsors
Ipsen
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
: * Patient diagnosed with spasticity related to any cause except cerebral palsy. * Patient initiated on treatment with either onaBoNT-A or aboBoNT-A during the study enrolment periods. * Patient is an adult aged ≥18 years old at the time of the first BoNT-A injection for spasticity * Patient has not received treatment with any type of BoNT-A 6 months prior to initiation of onaBoNT-A or aboBoNT-A. For patients with multiple courses of BoNT-A, separated by a gap of 6 months, only the first course will be evaluated in this study. * Patient is being treated at Haywood Hospital at index date and during follow-up for up to 24 weeks post-index date, with medical records available for review.
Exclusion criteria
: * Patient is participating in an interventional clinical trial of an investigational medicinal product for the treatment of spasticity at index date and/or during follow-up.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Average Goal Attainment Scale (GAS T) score 6 weeks | 6 weeks | GAS, a method that evaluates the attainment of priority goals that are of importance to the patient and has been previously used for the management of patients with limb spasticity. Rating is performed for each domain from -3 worse than at start to +2 much more than expected: clear improvement. |
| Average Goal Attainment Scale (GAS T) score 12 weeks | 12 weeks | GAS, a method that evaluates the attainment of priority goals that are of importance to the patient and has been previously used for the management of patients with limb spasticity. Rating is performed for each domain from -3 worse than at start to +2 much more than expected: clear improvement. |
| Proportion of patients who achieve GAS-T score ≥0 for impairment/ symptoms goal | 12 weeks | — |
| Proportion of patients who exceed GAS-T score ≥1 for impairment/ symptoms goal | 6 weeks | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Distribution of limb and type of muscles injected | Day 0 (first BoNT-A injection) and from baseline up to 24 weeks (reinjection) | Upper limb: shoulder girdle, shoulder, arm, forearm, hand; lower limb: hip, thigh, leg and foot |
| Proportion of patients who require re-injection between aboBoNT-A and onaBoNT-A | Week 6 and week 12 (re-injection) | — |
| Quality of Life (QoL) | From baseline up to 12 weeks | The EQ-5D-VAS is used to evaluate patients' quality of life. EQ-5D-VAS is one component of the EQ-5D-5L, a generic, preference-based measure of health-related quality of life. The questions are answered based on how the subject is feeling today. |
| Average total dose | Day 0 (first BoNT-A injection) and from baseline up to 24 weeks (reinjection) | — |
| Proportion of patients with ≥1 unscheduled visit | From baseline up to end of the study (up to 24 weeks) | — |
| Proportion of patients with at least the same, or at least better satisfaction with their treatment as measured using a Likert scale | From baseline up to 12 weeks | A Likert scale is used to record patient's satisfaction with his/her progress, and the patient's best response (since index date) and response now (at the time of the review) on a five-category scale: From Much worse to Much better |
| Average number of unscheduled visits | From baseline up to end of the study (up to 24 weeks) | — |
| Average dose per limb and per type of muscle injected | Day 0 (first BoNT-A injection) and from baseline up to 24 weeks (reinjection) | — |
| Distribution of vials used | Day 0 (first BoNT-A injection) and from baseline up to 24 weeks (reinjection) | If Dysport® 300U / 500U, if Botox® 50U / 100U / 200U |
| Distribution of localisation methods | Day 0 (first BoNT-A injection) and from baseline up to 24 weeks (reinjection) | Ultrasound, electrostimulation, palpation, electromyography |
Countries
United Kingdom
Outcome results
None listed